Latest Ratios: P/E Ratio -13.5x · EV/EBITDA N/A · ROE N/A. (1996–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $392M | $96M | $331M | $348M | $165M | $292M | $416M | $620M | $691M | $50M | $41M |
| Enterprise Value | $428M | $132M | $363M | $368M | $148M | $238M | $307M | $548M | $671M | $30M | $36M |
| P/E Ratio → | -13.48 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 4.63 | 1.34 | 5.16 | 6.93 | 4.79 | 8.84 | 14.24 | 43.45 | 88.28 | 29.27 | 26.72 |
| P/B Ratio | — | — | 73.64 | 7.08 | 1.95 | 2.79 | 3.60 | 8.56 | 33.18 | 1.94 | 6.16 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.84 | 5.65 | 7.34 | 4.29 | 7.20 | 10.49 | 38.42 | 85.70 | 17.58 | 23.51 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 82.1% | 82.1% | 85.8% | 84.5% | 82.4% | 81.5% | 79.6% | 79.2% | 76.8% | 41.2% | 57.2% |
| Operating Margin | -59.4% | -59.4% | -88.1% | -85.1% | -79.9% | -76.1% | -90.8% | -299.2% | -466.4% | -812.0% | -1073.2% |
| Net Profit Margin | -67.8% | -67.8% | -96.3% | -70.6% | -77.5% | -76.1% | -90.9% | -294.7% | -458.6% | -1370.8% | -975.0% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | -231.0% | -52.9% | -28.2% | -22.8% | -28.3% | -90.2% | -154.0% | -143.9% | -222.0% |
| ROA | -71.4% | -71.4% | -64.6% | -33.7% | -24.9% | -20.8% | -25.6% | -77.7% | -125.9% | -113.3% | -161.5% |
| ROIC | -114.8% | -114.8% | -80.3% | -46.8% | -34.9% | -66.6% | -615.7% | -4788.2% | -841.9% | -273.7% | -561.6% |
| ROCE | -159.7% | -159.7% | -71.6% | -45.9% | -28.3% | -22.3% | -27.5% | -88.9% | -150.1% | -79.6% | -231.2% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | 10.22 | 0.86 | 0.01 | 0.02 | 0.01 | 0.03 | — | 0.01 | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | 7.10 | 0.41 | -0.20 | -0.51 | -0.95 | -0.99 | -0.97 | -0.77 | -0.74 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -8.71 | -8.71 | -10.53 | -29.90 | -1663.31 | -864.69 | -1205.59 | — | -933.20 | — | — |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.57 | 0.57 | 2.83 | 7.88 | 8.18 | 10.07 | 16.42 | 10.17 | 5.38 | 7.75 | 3.72 |
| Quick Ratio | 0.46 | 0.46 | 2.47 | 7.46 | 7.98 | 9.84 | 16.20 | 10.02 | 5.22 | 7.35 | 3.19 |
| Cash Ratio | 0.29 | 0.29 | 1.78 | 6.75 | 7.42 | 9.31 | 14.99 | 9.55 | 4.50 | 5.16 | 1.94 |
| Asset Turnover | — | 1.27 | 0.81 | 0.45 | 0.35 | 0.28 | 0.23 | 0.17 | 0.30 | 0.05 | 0.15 |
| Inventory Turnover | 1.85 | 1.85 | 1.25 | 1.39 | 2.84 | 2.86 | 3.61 | 2.64 | 2.45 | 0.64 | 0.49 |
| Days Sales Outstanding | — | 46.42 | 67.96 | 57.66 | 52.60 | 37.87 | 98.43 | 64.16 | 118.27 | 69.74 | 52.60 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $28M | $26M | $25M | $25M | $24M | $20M | $20M | $22M | $9M | $7M |
Includes 30+ ratios · 30 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying RCEL stock.
Avita Medical Inc.'s current P/E ratio is -13.5x. This places it at the 50th percentile of its historical range.
Based on historical data, Avita Medical Inc. is trading at a P/E of -13.5x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Avita Medical Inc. has 82.1% gross margin and -59.4% operating margin.
Key Metrics
Top Statement Risk
Negative equity against collapsing liquidity
Metrics are mathematically derived from official filings.
Sales Multiple Carries Loss-Making Profile
Because trailing earnings are negative, RCEL's -8.72X P/E is uninterpretable, leaving the 5.27X price-to-sales ratio as the operative multiple; per market data compiled for the medical device peer set, that sales multiple prices Avita far above the near-0.8X book value attaching to XTNT.
A 5.27X sales multiple is difficult to justify against a business generating roughly -35% net margins, and with EV/EBITDA and forward P/E both unavailable, investors are effectively pricing optionality on future commercialization rather than present earning power. The absence of a usable earnings or EBITDA anchor means the discount to any profitability benchmark is unknowable today, so the sales multiple should be stress-tested against the cash burn implied by the negative FCF margin of -16.6%.
Gross Margin Erodes as Overhead Falls Short
Operating margin improved to -31.6% in 2026Q2 from -155.0% in 2024Q1, yet net margin of -35.3% still implies losses on every dollar sold; according to recent SEC filings, gross margin slipped to 81.9% from 87.6% two years earlier, a 570bp fade operating leverage cannot offset.
The narrowing operating loss reflects overhead reduction more than pricing power, since gross margin has fallen in roughly five of the ten quarters observed while revenue recovered, suggesting the unit economics themselves are weakening rather than merely being scaled. The consistently negative gap between operating and net margin, wider than three points in several quarters, points to material non-operating items that make adjusted or headline profitability readings unreliable as a measure of true earning power.
ROIC Deepens Negative Despite Revenue Recovery
ROIC of -36.5% in 2026Q2 remains far below the -19.7% reading of 2024Q4, indicating that capital deployed into the platform appears to be destroying rather than compounding value; as reported in Avita's financial statements, asset turnover of 0.44 cannot rescue returns while operating margins stay negative.
The deterioration in ROIC alongside rising asset turnover implies the driver is margin, not efficiency: the company is moving assets faster but converting them into deeper losses per unit of capital employed. With equity already negative, ROE is uninformative and effectively undefined, so ROIC against invested capital is the only defensible return measure — and its persistent sub--30% territory suggests no path to a positive cost-of-capital spread on current operations.
Payables Stretch Compresses Cash Cycle
The cash conversion cycle collapsed from 206 days in 2024Q1 to 16 days in 2026Q2, driven by DIO falling to 132 days from 384 and DSO to 41 from 71, while DPO of 158 days still exceeds receivable collection by nearly four times, per Avita's quarterly disclosures.
A 16-day cycle could superficially read as best-in-class working capital management, but the composition suggests supplier financing and inventory drawdown are subsidizing operations rather than structural process gains, a pattern that warrants investigation into whether payables terms are sustainable. The simultaneous fall in DIO and DPO from their 2024–2025 peaks may indicate inventory is being liquidated to fund the burn, which would flatter the cycle while eroding the manufacturing base underpinning gross margin.
Liquidity Buffer Inverts Into Deficit
The current ratio fell from 7.25 in 2024Q1 to 0.41 in 2026Q2 with the quick ratio at 0.34, meaning circulating assets cover barely two-fifths of short-term obligations; according to Avita's reported balance sheets, this sits alongside $9.1M of cash against $75.6M of total liabilities.
The relatively small spread between current and quick ratios implies inventory is not the dominant current asset cushion, so even liquidating remaining inventory would not restore coverage — a materially worse stress profile than the headline current ratio alone suggests. Under severe stress, coverage would hinge on the ability to roll or restructure obligations, and with interest coverage of -4.22X confirming earnings cannot service debt, investors should monitor whether liquidity is being managed through payable extension rather than genuine asset recovery.
P/E Misapplied to Pre-Profit Device Makers
The ratio most commonly misread for this business model is the P/E, whose -8.72X reading measures loss magnitude rather than cheapness or richness; as peer market data shows XTNT at 9.17X earnings, any RCEL earnings multiple would mechanically swing toward zero as losses narrow, per compiled comparisons.
For a commercial-stage device company still funding SG&A above revenue, the P/E obscures the real questions of cash runway, gross margin trajectory, and the revenue scale required to reach breakeven, none of which the multiple captures. EV/EBITDA is nearly as misleading while EBITDA remains negative, so sales-based measures adjusted for burn — such as EV/Sales net of quarterly free cash outflow — would better frame what the market is actually paying for.